New Delhi: Reviewing the justification presented by the drug major Intas Pharmaceuticals for not conducting the initial phase of clinical studies of the ophthalmic drug Bevacizumab injection, 25 mg/mL, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to demonstrate the safety and adequacy of the dose through initial phase clinical studies before carrying out Phase III clinical trials for the proposed drug.This came…
Read More…
CDSCO Panel Tells Intas Pharmaceuticals on Bevacizumab injection
